Tucotuzumab celmoleukin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tucotuzumab celmoleukin
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target EpCAM
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
KEGG
Chemical and physical data
Formula C7812H12124N2044O2408S60
Molar mass 175.1 kg/mol
  (verify)

Tucotuzumab celmoleukin is an anti-cancer drug. It is a fusion protein of a humanized monoclonal antibody (tucotuzumab) and an interleukin-2 (celmoleukin).[1][2][3]

This drug was developed by EMD Pharmaceuticals.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Tucotuzumab Celmoleukin, American Medical Association.
  2. ^ ClinicalTrials.gov
  3. ^ National Cancer Institute: Definition of tucotuzumab celmoleukin